Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Oxford Brain Diagnostics, Oxford Centre for Innovation, Oxford, UK.
Hum Brain Mapp. 2021 Mar;42(4):967-977. doi: 10.1002/hbm.25271. Epub 2020 Nov 11.
The aim of this research was to test a novel in-vivo brain MRI analysis method that could be used in clinical cohorts to investigate cortical architecture changes in patients with Alzheimer's Disease (AD). Three cohorts of patients with probable AD and healthy volunteers were used to assess the results of the method. The first group was used as the "Discovery" cohort, the second as the "Test" cohort and the last "ATN" (Amyloid, Tau, Neurodegeneration) cohort was used to test the method in an ADNI 3 cohort, comparing to amyloid and Tau PET. The method can detect altered quality of cortical grey matter in AD patients, providing an additional tool to assess AD, distinguishing between these and healthy controls with an accuracy range between good and excellent. These new measurements could be used within the "ATN" framework as an index of cortical microstructure quality and a marker of Neurodegeneration. Further development may aid diagnosis, patient selection, and quantification of the "Neurodegeneration" component in response to therapies in clinical trials.
本研究旨在测试一种新的基于活体大脑 MRI 的分析方法，该方法可用于临床队列，以研究阿尔茨海默病（AD）患者的皮质结构变化。使用了三组疑似 AD 患者和健康志愿者来评估该方法的结果。第一组被用作“发现”队列，第二组被用作“测试”队列，最后一组“ATN”（淀粉样蛋白、tau、神经退行性变）队列用于在 ADNI 3 队列中测试该方法，与淀粉样蛋白和 tau PET 进行比较。该方法可以检测 AD 患者皮质灰质质量的改变，为评估 AD 提供了一种额外的工具，其对 AD 患者与健康对照组的区分准确性在良好到优秀之间。这些新的测量指标可在“ATN”框架内作为皮质微结构质量的指标和神经退行性变的标志物。进一步的发展可能有助于诊断、患者选择以及在临床试验中对治疗的“神经退行性变”成分进行量化。
